Hereditary Transthyretin Amyloidosis (hATTR)

Hereditary Transthyretin Amyloidosis (hATTR)

Introduction

Hereditary Transthyretin Amyloidosis (Hattr) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Hereditary transthyretin amyloidosis (hATTR) is a progressive, systemic, and ultimately fatal protein misfolding disease caused by autosomal dominant mutations in the TTR gene [@hawkins]
encoding transthyretin. The disease is characterized by the extracellular deposition of amyloid fibrils composed of misfolded transthyretin protein in multiple organs, most [@adams2019]
commonly the peripheral nerves, autonomic nervous system, heart, kidneys, and gastrointestinal tract. hATTR represents one of the most important hereditary systemic amyloidoses and [@ruberg2012]
serves as a paradigmatic model for understanding protein aggregation and misfolding in human disease [@pinto]. [@plantbordeneuve2011]

The disease was first described by Corino de Andrade in 1952 in families from northern Portugal, where the Val30Met mutation remains endemic. Since then, over 140 pathogenic TTR mutations have been identified worldwide, establishing hATTR as a genetically heterogeneous condition with remarkable phenotypic variability. The global prevalence is estimated at approximately 50,000 individuals, though the disease is significantly underdiagnosed, particularly in non-endemic regions. [@buxbaum2017]

Molecular Pathogenesis

Transthyretin Structure and Function

Hereditary Transthyretin Amyloidosis (hATTR)

Introduction

Hereditary Transthyretin Amyloidosis (Hattr) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Hereditary transthyretin amyloidosis (hATTR) is a progressive, systemic, and ultimately fatal protein misfolding disease caused by autosomal dominant mutations in the TTR gene [@hawkins]
encoding transthyretin. The disease is characterized by the extracellular deposition of amyloid fibrils composed of misfolded transthyretin protein in multiple organs, most [@adams2019]
commonly the peripheral nerves, autonomic nervous system, heart, kidneys, and gastrointestinal tract. hATTR represents one of the most important hereditary systemic amyloidoses and [@ruberg2012]
serves as a paradigmatic model for understanding protein aggregation and misfolding in human disease [@pinto]. [@plantbordeneuve2011]

The disease was first described by Corino de Andrade in 1952 in families from northern Portugal, where the Val30Met mutation remains endemic. Since then, over 140 pathogenic TTR mutations have been identified worldwide, establishing hATTR as a genetically heterogeneous condition with remarkable phenotypic variability. The global prevalence is estimated at approximately 50,000 individuals, though the disease is significantly underdiagnosed, particularly in non-endemic regions. [@buxbaum2017]

Molecular Pathogenesis

Transthyretin Structure and Function

Transthyretin (TTR) is a 55-kDa homotetrameric protein primarily synthesized in the liver, choroid plexus, and retinal pigment epithelium. Under physiological conditions, TTR circulates as a stable tetramer in the plasma and cerebrospinal fluid, where it serves as a transport protein for thyroxine (T4) and retinol-binding protein–retinol complex (vitamin A). The tetrameric structure is critical for TTR stability and function, with each monomer consisting of 127 amino acid residues arranged in a beta-sheet-rich structure [@adams2019]. [@karam]

Amyloid Fibril Formation

The pathogenesis of hATTR involves a cascade of molecular events beginning with destabilization of the TTR tetramer: [@garciapavia]

The amyloidogenic process in hATTR shares mechanistic parallels with amyloid in [alzheimers](/diseases/alzheimers-disease) and [alpha-synuclein](/proteins/alpha-synuclein) aggregation in [parkinsons](/diseases/parkinsons-disease), underscoring conserved principles of protein misfolding across neurodegenerative diseases [@ruberg2012]. [@maurer]

Mechanisms of Nerve Damage

Peripheral nerve injury in hATTR polyneuropathy results from multiple pathological mechanisms: [@maurera]

• Direct mechanical compression: Amyloid deposits compress nerve fibers within the endoneurium and perineurium
• Ischemic injury: Amyloid infiltration of the vasa nervorum compromises the blood supply to peripheral nerves
• Toxic oligomer effects: Pre-fibrillar TTR oligomers may directly damage neuronal membranes and induce [oxidative-stress](/mechanisms/oxidative-stress)
• Schwann cell dysfunction: Amyloid deposition disrupts Schwann cell integrity, leading to demyelination and impaired axonal support
• Autonomic ganglion involvement: Amyloid deposits in sympathetic and parasympathetic ganglia cause autonomic dysfunction

Genetics and Epidemiology

TTR Mutations

Over 140 amyloidogenic TTR mutations have been identified, with significant genotype-phenotype correlations: [@coelho]

| Mutation | Phenotype | Endemic Region | Onset | [@fontana]
|----------|-----------|----------------|-------|
| Val30Met (V30M) | Polyneuropathy-predominant | Portugal, Japan, Sweden | 25–35 (early-onset) or 50–60+ (late-onset) |
| Val122Ile (V122I) | Cardiomyopathy-predominant | African Americans (3–4% carrier rate) | 60–70 |
| Thr60Ala (T60A) | Mixed cardiac/neuropathy | Ireland, Appalachian USA | 45–65 |
| Ser77Tyr (S77Y) | Cardiac-predominant | — | 50–70 |
| Ile84Ser (I84S) | Mixed phenotype | — | 40–60 |
| Leu111Met (L111M) | Cardiac-predominant | Denmark | 50–70 |

The Val30Met mutation accounts for approximately 70% of all hereditary ATTR cases worldwide. Three major endemic foci have been identified: northern Portugal (Póvoa de Varzim), northern Sweden (Skellefteå), and Japan (Nagano and Kumamoto prefectures) [@plantbordeneuve2011].

The Val122Ile variant is particularly significant from a public health perspective, as it is carried by 3–4% of African Americans (approximately 1.5 million individuals in the United States), making it one of the most common pathogenic mutations in any gene in the general population [@buxbaum2017].

Penetrance and Modifiers

hATTR displays variable penetrance influenced by geographic origin, sex, and genetic modifiers. In Portuguese kindreds, penetrance approaches 80% by age 50, while in Swedish families, penetrance may be as low as 2% at age 30, increasing to 50% by age 60. [Male sex is associated with earlier onset and higher penetrance in most populations. Non-coding variants in the TTR gene and modifier genes affecting proteostasis pathways may influence disease expression] [@karam].

Clinical Manifestations

Polyneuropathy

The neuropathic phenotype is the hallmark of hATTR, particularly with the Val30Met mutation:

• Length-dependent sensorimotor polyneuropathy: Begins in the feet with loss of pain and temperature sensation (small fiber neuropathy), progressing to involve large fibers with loss of proprioception and vibration
• Progressive motor weakness: Ascending weakness leading to gait difficulty, foot drop, and eventually wheelchair dependence
• Neuropathic pain: Often severe, with burning, shooting, and lancinating qualities
• Carpal tunnel syndrome: Bilateral carpal tunnel syndrome may precede systemic symptoms by years and represents an important diagnostic clue

Autonomic Neuropathy

Autonomic dysfunction is a prominent and often disabling feature:

• Orthostatic hypotension: Can be severe and treatment-limiting
• Gastrointestinal dysmotility: Alternating diarrhea and constipation, early satiety, nausea, and unintentional weight loss
• Erectile dysfunction: Often an early symptom in males
• Neurogenic bladder: Urinary retention and recurrent infections
• Anhidrosis: Impaired sweating with heat intolerance

Cardiomyopathy

Cardiac involvement is present in virtually all hATTR patients at some stage and is the primary determinant of prognosis:

• Infiltrative cardiomyopathy: Amyloid deposition causes progressive biventricular wall thickening with restrictive physiology
• Heart failure: Progressive diastolic and eventually systolic dysfunction
• Cardiac arrhythmias: Atrial fibrillation, conduction block, and ventricular arrhythmias
• Median survival: 2–6 years from cardiac involvement diagnosis, depending on disease stage.

Other Organ Involvement

• Ocular: Vitreous opacities, glaucoma, dry eye (from choroid plexus and retinal TTR production)
• Renal: Proteinuria and progressive nephropathy
• Leptomeningeal: CNS amyloid angiopathy (particularly with certain mutations)
• Musculoskeletal: Lumbar spinal stenosis, joint stiffness

Diagnosis

Clinical Assessment

Diagnosis requires a high index of suspicion, particularly in non-endemic areas. Red flags include:

• Progressive sensorimotor polyneuropathy with autonomic features
• Unexplained cardiomyopathy with increased wall thickness
• Bilateral carpal tunnel syndrome
• Family history of neuropathy, cardiomyopathy, or early death

Confirmatory Tests

Staging

The Coutinho staging system for polyneuropathy:

• Stage 1: Sensory polyneuropathy limited to lower limbs; ambulatory
• Stage 2: Sensorimotor polyneuropathy with assistive walking devices needed
• Stage 3: Wheelchair-bound or bedridden; severe sensorimotor and autonomic neuropathy

Treatment

TTR Gene Silencers

RNA interference (RNAi) and antisense oligonucleotide (ASO) therapies reduce hepatic TTR production by 80–90%:

• Patisiran (Onpattro): First FDA-approved RNAi therapy (2018). Demonstrated significant improvement in polyneuropathy disability scores in the APOLLO trial. Administered as IV infusion every 3 weeks
• Vutrisiran (Amvuttra): Next-generation RNAi with subcutaneous delivery every 3 months. Shown non-inferior to patisiran in the HELIOS-A trial with improved convenience
• Inotersen (Tegsedi): Antisense oligonucleotide with weekly subcutaneous injection; requires platelet monitoring due to thrombocytopenia risk
• Eplontersen (Wainua): Next-generation [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy) with monthly subcutaneous dosing and improved safety profile

TTR Stabilizers

Small molecules that bind to the thyroxine-binding sites on TTR, stabilizing the tetramer and preventing dissociation:

• Tafamidis (Vyndaqel/Vyndamax): FDA-approved for ATTR cardiomyopathy (2019) based on the ATTR-ACT trial showing reduced all-cause mortality and cardiovascular hospitalizations
• Diflunisal: NSAID with TTR-stabilizing properties; used off-label
• Acoramidis (Attruby): Novel TTR stabilizer with greater occupancy of TTR binding sites; FDA-approved for ATTR-CM in 2024

Liver Transplantation

Orthotopic liver transplantation was the first disease-modifying treatment for hATTR, removing the primary source of mutant TTR. However, wild-type TTR produced by the donor liver can continue to deposit as amyloid, and the procedure carries significant morbidity and mortality. Liver transplantation has been largely supplanted by pharmacological therapies but remains an option in certain circumstances [@garciapavia].

Emerging Therapies

• CRISPR-based [crispr-gene-editing](/therapeutics/crispr-gene-editing): NTLA-2001 (vu-tmir), an in vivo CRISPR-Cas9 therapy targeting the TTR gene in hepatocytes, has shown >90% TTR knockdown after a single intravenous dose in Phase 1 trials
• TTR amyloid fibril disruptors: Agents designed to clear existing amyloid deposits
• Combination approaches: Stabilizer + silencer combinations are under investigation

Relationship to Other Neurodegenerative Diseases

hATTR provides critical insights into broader neurodegenerative mechanisms:

• Protein misfolding paradigm: TTR amyloidogenesis parallels [amyloid-beta](/proteins/amyloid-beta) and tau] aggregation pathways
• Wild-type TTR amyloidosis (ATTRwt): Previously known as senile cardiac amyloidosis, ATTRwt involves deposition of non-mutant TTR, predominantly in the heart of elderly men, with an estimated prevalence of 10–25% in heart failure with preserved ejection fraction patients over age 80
• [Prion-like spreading](/mechanisms/prion-like-spreading): TTR amyloid may propagate through prion-like seeding mechanisms
• Therapeutic model: The success of gene silencing and protein stabilization in hATTR has inspired analogous approaches for [alzheimers](/diseases/alzheimers-disease), [huntington-pathway](/mechanisms/huntington-pathway), and [als](/diseases/amyotrophic-lateral-sclerosis)
• Proteostasis network: hATTR highlights the role of the [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) and [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy) in managing misfolded proteins

Prognosis

Without treatment, hATTR is invariably fatal, with median survival of 7–12 years from symptom onset for Val30Met neuropathy and 2–6 years for cardiac-predominant phenotypes. Disease-modifying therapies have dramatically altered the natural history: TTR gene silencers can stabilize or improve polyneuropathy, and TTR stabilizers reduce mortality in ATTR cardiomyopathy by approximately 30% over 30 months [@maurer].

See Also

• [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [crispr-gene-editing](/therapeutics/crispr-gene-editing)

External Links

• [GeneReviews: Hereditary Transthyretin Amyloidosis](https://www.ncbi.nlm.nih.gov/books/NBK1194/)
• [OMIM: Transthyretin Amyloidosis](https://omim.org/entry/105210)
• [Amyloidosis Foundation](https://amyloidosis.org/)
• [ClinicalTrials.gov: hATTR Amyloidosis](https://clinicaltrials.gov/search?cond=Hereditary+Transthyretin+Amyloidosis)

Background

The study of Hereditary Transthyretin Amyloidosis (Hattr) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Recent advances in Hereditary Transthyretin Amyloidosis (hATTR) have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References